2025 is a remarkable milestone in the fight against chronic myeloid leukemia - the 25th anniversary of tyrosine kinase inhibitors (TKIs). The story of TKI development is one of collaboration and courage. A story that formed the basis of the iCMLf, and one that we hope to emulate as we continue working to improve outcomes for people with CML. 

Over the coming year we will share highlights of the development, impact and future opportunities of this incredible therapy. To begin, we share a message from Professor Jorge Cortes and Professor Brian Druker.

A Special Message from Professor Jorge Cortes, and Professor Brian Druker:

As we mark the 25th anniversary of TKIs, we reflect on one of the most transformative breakthroughs in the treatment of cancer. Twenty-five years ago, the introduction of imatinib (Gleevec/Glivec) changed the course of CML forever, turning a once-fatal disease into a manageable condition for most patients.

This achievement was only possible through an extraordinary collaboration between scientists, clinicians, patients and the pharmaceutical industry. Together, we reimagined what was possible for people living with CML. The story of TKIs is a testament to the power of teamwork, perseverance, and the unwavering commitment to improving patient outcomes.

The impact of TKIs is undeniable. They have saved countless lives and improved quality of life, and inspired hope for people living with CML. Yet, the journey is not over. Access to these life-saving treatments remains a challenge for many, and ensuring they are used effectively is equally critical. We must continue to work together to make both access to TKIs and expert CML care a reality for every person who needs them, as we continue seeking answers for the many remaining questions in CML to make cure a reality for all patients.

At the iCMLf, everything we do is built on the legacy of TKIs. From advancing research to educating physicians and advocating for equitable care, optimising TKI therapy continues to inspire our mission. As we celebrate the 25 year milestone, we also look to the future - a future where a cure, alongside this extraordinary treatment, is within reach.

Thank you for being part of this journey with us. Together, we celebrate the past, honor the present, and strive for an even brighter future.

Professor Jorge Cortes
Chairman, iCMLf
Director, Georgia Cancer Center   
Augusta, GA, USA  

Professor Brian Druker
Lead developer of imatinib
OHSU Knight Cancer Institute
Portland, OR, USA

Stay tuned for stories, events, and opportunities to get involved in this year of celebration.

Join us in celebrating 25 years of TKIs - a legacy of hope and progress.